Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential binding of prohibitin-2 to estrogen receptor α and to drug-resistant ERα mutants.

Biochemical and biophysical research communications - 7 Aug 2015

Chigira Takeru, Nagatoishi Satoru, Tsumoto Kouhei

Abstract excerpt

Endocrine resistance is one of the most challenging problems in estrogen receptor alpha (ERα)-positive breast cancer. The transcriptional activity of ERα is controlled by several coregulators, including prohibitin-2 (PHB2). Because of its ability to repress the transcriptional activity of activated ERα, PHB2 is a promising antiproliferative agent. In this study, were analyzed the interaction of PHB2 with ERα and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calorimetry, Differential Scanning
Share to Circular Dichroism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Estrogen Receptor alpha

Share to Prohibitins

Share to Recombinant Proteins

Share to Repressor Proteins

Share to Thermodynamics

Source

Identifiers

PMID: 26049107
DOI: 10.1016/j.bbrc.2015.06.002

Genes

PHB2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential binding of prohibitin-2 to estrogen receptor α and to drug-resistant ERα mutants.PMID 26049107Read ↗

The SERM/SERD Bazedoxifene Disrupts ESR1 Helix 12 to Overcome Acquired Hormone Resistance in Breast Cancer CellsSemantic proximity Read ↗

Somatic estrogen receptor α mutations that induce dimerization promote receptor activity and breast cancer proliferation.Semantic proximity Read ↗

Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer CellsSemantic proximity Read ↗

Elucidation of the structural dynamics of mutations in PHB2 protein associated with growth suppression and cancer progression.Semantic proximity Read ↗

HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocksSemantic proximity Read ↗

Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer CellsSemantic proximity Read ↗

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers.Semantic proximity Read ↗

The natural L370F ERα Variant Confers Endocrine Resistance and Sensitivity to ATRA in Metastatic Breast Cancer CellsSemantic proximity Read ↗

pH and the Breast Cancer Recurrent Mutation D538G Affect the Process of Activation of Estrogen Receptor α.Semantic proximity Read ↗

Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance.Semantic proximity Read ↗

Defining the Energetic Basis for a Conformational Switch Mediating Ligand-Independent Activation of Mutant Estrogen Receptors in Breast Cancer.Semantic proximity Read ↗

Mitoxantrone inhibits and downregulates ER <i>α</i> through binding at the DBD-LBD interfaceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.